CASI Pharmaceuticals CASIF
OTC CASIF
$0.12 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

CASI Pharmaceuticals (CASIF) Non-Current Deffered Revenue (2021)

Updated

CASI Pharmaceuticals (CASIF) reported Non-Current Deffered Revenue of $2.83 million for Q4 2021.

Analysis

CASI Pharmaceuticals (CASIF) Non-Current Deffered Revenue (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn -
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn -
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn -
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn -
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -
10 CASI Pharmaceuticals 2.47 Mn -18.36 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 2.83 Mn
API Access

CASI Pharmaceuticals Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=CASIF&period=max&api_key=YOUR_API_KEY